Eppie Bass, APRN, explains how nurses can counsel patients on flu-like symptoms vs warning signs with nogapendekin alfa inbakicept-pmln and BCG.
News|Articles|September 3, 2026
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
Author(s)Alex Biese
Fact checked by: By ONN Staff
Oncology nursing guide to the FDA approval of zanidatamab-hrii for HER2+ gastroesophageal cancers, featuring insights from Joe Chichioco, RN, MPH.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) has approved the HER2-directed bispecific antibody zanidatamab-hrii (Ziihera) as a first-line therapy for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.
Related to this article
A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.
Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS efficacy data.
Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology nursing takeaways.
Discover how equine-assisted services support patients with cancer by improving emotional wellness, building confidence, and enhancing quality of life.
Advertisement
Advertisement